AR042345A2 - Un procedimiento para la preparacion de una composicion farmaceutica para el tratamiento de aterosclerosis que contiene 8.9 - dehidroesterona o sus sales de la misma - Google Patents

Un procedimiento para la preparacion de una composicion farmaceutica para el tratamiento de aterosclerosis que contiene 8.9 - dehidroesterona o sus sales de la misma

Info

Publication number
AR042345A2
AR042345A2 ARP030104530A ARP030104530A AR042345A2 AR 042345 A2 AR042345 A2 AR 042345A2 AR P030104530 A ARP030104530 A AR P030104530A AR P030104530 A ARP030104530 A AR P030104530A AR 042345 A2 AR042345 A2 AR 042345A2
Authority
AR
Argentina
Prior art keywords
preparation
treatment
pharmaceutical composition
dehydroesterone
aterosclerosis
Prior art date
Application number
ARP030104530A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR042345A2 publication Critical patent/AR042345A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un procedimiento para la preparación de una composición farmacéutica para el tratamiento de la aterosclerosis que comprende poner en contacto 8,9-dehidroestrona o una sal farmacéuticamente aceptable de la misma en combinación con un vehículo farmacéutico aceptable.
ARP030104530A 1992-02-26 2003-12-09 Un procedimiento para la preparacion de una composicion farmaceutica para el tratamiento de aterosclerosis que contiene 8.9 - dehidroesterona o sus sales de la misma AR042345A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/841,694 US5210081A (en) 1992-02-26 1992-02-26 Alkali metal 8,9-dehydroestrone sulfate esters

Publications (1)

Publication Number Publication Date
AR042345A2 true AR042345A2 (es) 2005-06-15

Family

ID=25285489

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP9501333967A AR042262A2 (es) 1992-02-26 1995-10-24 Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
ARP030104530A AR042345A2 (es) 1992-02-26 2003-12-09 Un procedimiento para la preparacion de una composicion farmaceutica para el tratamiento de aterosclerosis que contiene 8.9 - dehidroesterona o sus sales de la misma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP9501333967A AR042262A2 (es) 1992-02-26 1995-10-24 Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis

Country Status (21)

Country Link
US (3) US5210081A (es)
EP (2) EP0628052B1 (es)
JP (1) JP3715645B2 (es)
KR (1) KR100256861B1 (es)
AR (2) AR042262A2 (es)
AT (2) ATE342272T1 (es)
AU (2) AU677181B2 (es)
CA (1) CA2089707A1 (es)
DE (2) DE69322497T2 (es)
DK (2) DK0628052T3 (es)
ES (2) ES2274555T3 (es)
FI (1) FI115915B (es)
GR (1) GR3029620T3 (es)
HU (2) HUT67553A (es)
LV (1) LV12240B (es)
MX (1) MX9300969A (es)
PT (1) PT864583E (es)
SG (1) SG49715A1 (es)
TW (1) TW257677B (es)
WO (1) WO1993017036A1 (es)
ZA (1) ZA93746B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210081A (en) * 1992-02-26 1993-05-11 American Home Products Corporation Alkali metal 8,9-dehydroestrone sulfate esters
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE4334823C2 (de) * 1993-10-09 1998-09-17 Schering Ag Verfahren zur Herstellung von Schwefelsäurehalbestern von Estrogenen
US5395831A (en) * 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5998639A (en) * 1995-11-06 1999-12-07 Akzo Nobel, N.V. Sulfatation of estrogen mixtures
AU703814B2 (en) * 1995-12-04 1999-04-01 Wyeth Antioxidant
DE19631542C1 (de) * 1996-07-25 1997-08-28 Schering Ag Verfahren zur Herstellung von 3-Sulfatoxy-estra-1,3,5(10)-trien-Derivaten II
DE19631543C1 (de) * 1996-07-25 1997-11-20 Schering Ag Verfahren zur Herstellung von 3-Sulfatoxy-estra-1,3,5(10)-trien-Derivaten I
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
ID18256A (id) * 1996-09-16 1998-03-19 American Home Prod Penggunaan dari 8,9-dehidro estron sebagai estrogen dengan hasil netral pada tingkat prolaktin
AR014096A1 (es) * 1996-10-11 2001-02-07 Wyeth Corp 17 alfa,8,9-deshidroestradiol y 17 beta delta 8,9 deshidroestradiol, el uso de los mismos para la manufactura de un medicamento, una composicionfarmaceutica que los comprende y un procedimiento para su preparacion.
ZA979204B (en) * 1996-10-16 1999-04-14 American Home Prod Use of 8,9-dehydroestrone in treating vasomotor symptoms
IL124213A (en) * 1997-05-02 2004-12-15 Akzo Nobel Nv Sulfation of estrogen mixtures
US6432643B1 (en) 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
US7989436B2 (en) * 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US6660726B2 (en) * 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US6855703B1 (en) * 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20030158432A1 (en) * 2002-01-08 2003-08-21 Leonard Thomas W. Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex
US8349819B2 (en) * 2002-10-09 2013-01-08 Dr. Reddy's Laboratories New York, Inc. Steroid extraction process from urine sources
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
WO2004091535A2 (en) * 2003-04-11 2004-10-28 Barr Laboratories, Inc. Methods of administering estrogens and progestins
MXPA06014229A (es) * 2004-06-07 2007-05-04 Wyeth Corp Revestimientos de azucar y metodos para estos.
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
WO2006084082A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
PE20070188A1 (es) * 2005-06-29 2007-03-16 Wyeth Corp Formulaciones de estrogenos conjugados y bazedoxifeno
EP2289486A1 (en) * 2005-12-27 2011-03-02 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
MX2009004960A (es) * 2006-11-07 2009-06-05 Wyeth Corp Revestimientos de azucar y metodos para los mismos.
US20080175908A1 (en) * 2007-01-12 2008-07-24 Wyeth Tablet-in-tablet compositions
US20080194533A1 (en) * 2007-02-09 2008-08-14 Wyeth Process for selective sulfation of aromatic hydroxyl groups
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
TW201127386A (en) 2009-10-27 2011-08-16 Wyeth Llc Bazedoxifene formulations with antioxidants

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2834712A (en) * 1953-05-27 1958-05-13 American Home Prod Urinary estrogen compositions and methods for preparing them
US3079410A (en) * 1960-04-02 1963-02-26 Hoechst Ag Process for stabilizing anionic and cationic ester salts of 21-hydroxy-20-ketosteroids in an aqueous solution
US3959322A (en) * 1960-09-22 1976-05-25 Herchel Smith Synthesis of 13-alkyl-gon-4-ones
DE1200476B (de) * 1961-04-10 1965-09-09 Frosst & Co Charles E Stabilisierung von trockenen Zubereitungen synthetischer Alkalisalze von OEstronsulfat
US3551459A (en) * 1962-10-04 1970-12-29 Herchel Smith 13-methyl-8-isogonanes
US3394153A (en) * 1965-08-18 1968-07-23 Merck & Co Inc Process for the preparation of d, 1-8-dehydroestrone, and intermediates obtained therefrom
NL6805153A (es) * 1968-04-10 1969-10-14
US3644618A (en) * 1968-10-29 1972-02-22 Frosst & Co Charles E Stable composition of synthetic sodium estrone sulfate
US3608077A (en) * 1969-11-13 1971-09-21 Syntex Corp Stabilization of metal steroid alcohol sulfates
US3649621A (en) * 1969-12-19 1972-03-14 American Home Prod Novel 3-cyclopentyl ethers of 13-alkylgon-poly-enes
GB1451109A (en) * 1973-08-17 1976-09-29 Rech Et Dapplications Scient S Derivatives of oestrone and their use in therapy
GB1528321A (en) * 1975-07-07 1978-10-11 Leo Ab Acylation process for the preparation of phenolic n,n-di-substituted carbamate esters
SE439586B (sv) * 1975-09-05 1985-06-24 Kanebo Ltd Sett att framstella ett stabilt farmaceutiskt torrpreparat av ett alkalimetallsalt av dehydroepiandrosteronsulfat
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
US5210081A (en) * 1992-02-26 1993-05-11 American Home Products Corporation Alkali metal 8,9-dehydroestrone sulfate esters

Also Published As

Publication number Publication date
FI943903L (fi) 1994-08-25
EP0864583A2 (en) 1998-09-16
ES2125975T3 (es) 1999-03-16
AU2007697A (en) 1997-07-03
ES2274555T3 (es) 2007-05-16
HK1011369A1 (en) 1999-07-09
AU711571B2 (en) 1999-10-14
AR042262A2 (es) 2005-06-15
DK0864583T3 (da) 2006-12-04
WO1993017036A1 (en) 1993-09-02
KR100256861B1 (ko) 2000-08-01
EP0628052B1 (en) 1998-12-09
HU9402457D0 (en) 1994-10-28
US5288717A (en) 1994-02-22
DE69334073D1 (de) 2006-11-23
ATE174342T1 (de) 1998-12-15
LV12240B (en) 1999-06-20
CA2089707A1 (en) 1993-08-27
DE69322497T2 (de) 1999-05-06
HU211971A9 (en) 1996-01-29
JPH07504197A (ja) 1995-05-11
AU677181B2 (en) 1997-04-17
ZA93746B (en) 1994-08-03
PT864583E (pt) 2007-01-31
MX9300969A (es) 1993-09-01
DE69334073T2 (de) 2007-02-01
US6169082B1 (en) 2001-01-02
FI943903A0 (fi) 1994-08-25
LV12240A (lv) 1999-03-20
JP3715645B2 (ja) 2005-11-09
ATE342272T1 (de) 2006-11-15
SG49715A1 (en) 1998-06-15
HK1020282A1 (en) 2000-04-07
US5210081A (en) 1993-05-11
DK0628052T3 (da) 1999-07-12
TW257677B (es) 1995-09-21
EP0864583B1 (en) 2006-10-11
EP0864583A3 (en) 2004-07-21
FI115915B (fi) 2005-08-15
AU3726093A (en) 1993-09-13
DE69322497D1 (de) 1999-01-21
HUT67553A (en) 1995-04-28
KR950700318A (ko) 1995-01-16
GR3029620T3 (en) 1999-06-30
EP0628052A1 (en) 1994-12-14

Similar Documents

Publication Publication Date Title
AR042345A2 (es) Un procedimiento para la preparacion de una composicion farmaceutica para el tratamiento de aterosclerosis que contiene 8.9 - dehidroesterona o sus sales de la misma
CO4950529A1 (es) Dihidropirimidinas y productos que las contienen
AR038434A2 (es) Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina
PT83872A (de) Arzneimittel
ES2191682T3 (es) Nueva formulacion farmaceutica.
ATE124405T1 (de) 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel.
MX9300014A (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.
NO944430L (no) 4-mercaptoacetylamino-[2Åbenzazepinon(3)-derivater, og anvendelse som enkefalinaseinhibitorer
LT2063B (lt) Guanino dariniu arba ju farmaceutiskai tinkamu drusku gavimo budas
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
DK345588A (da) 1,2-diketo-derivater til anvendelse som renin-inhibitorer
MX9202644A (es) Metodo para lisar microbacterias.
FI884720A0 (fi) Kompositioner foer anvaendning som kontrastmedel.
PT91302A (pt) Processo para a preparacao de composicoes farmaceuticas contendo imidazo {2,1-a} isoquinolinas substituidas por 5-heteroarilo ou 5-arilo
ITBO930061A1 (it) Metodo e macchina per la realizzazione di pacchetti doppi di sigarette.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
AR003418A1 (es) Composición farmacéutica con actividad antiepiléptica que contiene ácido r(-)-n- (4,4-di(3-metiltien-2-il) but-3-enil)-nipecótico o sus sales y el procedimiento para su preparación.
CO4290351A1 (es) Proceso
YU48915B (sh) Sulfonilkarbamid i postupak za njegovo dobijanje
ES2084878T3 (es) Sal colina de diclofenac, un procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
DK0466730T3 (da) Geminale biphosphonsyrer og derivater deraf som anti-arthritismidler
ES2052670T3 (es) Utilizacion de derivados de 2-pirimidinil-1-piperazina.
IL89401A0 (en) Medicaments containing 1,4-dihydropyridine derivatives for the treatment of alcohol addiction
MX9102087A (es) Complejos que contienen acidos s(+) fenilalcanos y acidos alfa-hidroxi alcanos.
AR005866A1 (es) Composicion farmaceutica antioxidante